Research Topics
| Dirk De RuysscherSummaryAffiliation: University Hospital Maastricht Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancerSuresh Senan
Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, P O Box 7057, 1007 MB Amsterdam, The Netherlands
Radiother Oncol 71:139-46. 2004..To review the literature on techniques used in high-dose radiotherapy of lung cancer in order to develop recommendations for clinical practice and for use in research protocols...
Critical review of PET-CT for radiotherapy planning in lung cancerSuresh Senan
Department of Radiation Oncology, VU University Medical Center, De Boelelaan 1117, Post Box 7057, 1007 MB Amsterdam, The Netherlands
Crit Rev Oncol Hematol 56:345-51. 2005..Data on the role of PET scans for radiotherapy planning for limited stage small-cell lung cancer is limited, although the incorporation of FDG-PET positive regions would appear to be reasonable...
Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot studyDirk De Ruysscher
Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center, Maastricht, The Netherlands
Radiother Oncol 91:415-20. 2009..As Radiation-Induced Lung Toxicity (RILT) is dose-limiting for radiotherapy (RT) of lung cancer and current parameters are only moderately associated with RILT, we sought for novel parameters associated with RILT...
State of the art radiation therapy for lung cancer 2012: a glimpse of the futureDirk De Ruysscher
Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Clin Lung Cancer 14:89-95. 2013....
Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based studyDirk De Ruysscher
Department of Radiation Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
Radiother Oncol 102:228-33. 2012..Individualised, isotoxic, accelerated radiotherapy (INDAR) allows the delivery of high biological radiation doses, but the long-term survival associated with this approach is unknown...
Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?D De Ruysscher
Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center Maastricht, Maastricht, The Netherlands
Strahlenther Onkol 188:564-7. 2012..A strong association between neutropenia and oesophagitis was previously shown, but external validation and further elucidation of the possible mechanisms are lacking...
Charged particles in radiotherapy: a 5-year update of a systematic reviewDirk De Ruysscher
Department of Radiation Oncology, MAASTRO, Maastricht University Medical Center, The Netherlands
Radiother Oncol 103:5-7. 2012..In our view, the aim should be to build enough proton therapy facilities with interest in research to further improve the treatment and to run the needed clinical trials...
PET scans in radiotherapy planning of lung cancerDirk De Ruysscher
Maastricht University Medical Center, Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands
Lung Cancer 75:141-5. 2012..However, care must be taken to avoid a variety of technical pitfalls and specific education is necessary, for clinicians and physicists alike...
Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patientsD De Ruysscher
Department of Radiotherapy, Maastro Clinic, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Ann Oncol 18:909-16. 2007..We therefore identified factors associated with the occurrence of acute dysphagia in lung cancer patients receiving radiotherapy alone or combined with chemotherapy...
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancerDirk De Ruysscher
Maastricht University Medical Center, Department of Radiation Oncology Maastro Clinic, GROW Research Institute, Maastricht, The Netherlands
Radiother Oncol 91:353-9. 2009..To determine what the influence is of dyspnea (CTCAE3.0) before high-dose radiotherapy (RT) on the incidence and severity of subsequent lung toxicity in patients with non-small cell lung cancer (NSCLC)...
High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancerD De Ruysscher
Department of Radiation Oncology, Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
Minerva Chir 66:341-5. 2011..Early results of INDAR with concurrent chemotherapy or with cetuximab are promising...
Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating studyDirk De Ruysscher
Department of Radiation Oncology, Maastro Clinic, Maastricht University Medical Center, Maastricht, The Netherlands
Radiother Oncol 93:389-95. 2009..Improved local tumor control (LC) improves survival of patients with non-small cell lung cancer (NSCLC). We estimated the capability of surgical and non-surgical options to improve LC further in this disease...
Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trialDirk De Ruysscher
Maastro Clinic, Maastricht, The Netherlands
Radiother Oncol 84:23-5. 2007..None of the endpoints differed significantly between both groups. However, due to the limited number of patients, no definitive conclusions can be drawn...
HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancerDirk De Ruysscher
Department of Radiation Oncology, University Hospital Maastricht, GROW, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 71:132-8. 2008..To determine the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer (NSCLC)...
Treatment of limited disease small cell lung cancerDirk De Ruysscher
Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Medical Center Maastricht, Maastricht, The Netherlands
Front Radiat Ther Oncol 42:173-9. 2010..With this treatment, 5-year survival rates of 25% can be achieved in patients with LD-SCLC...
Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trialDirk De Ruysscher
Maastro Clinic, Maastricht, The Netherlands
Radiother Oncol 80:307-12. 2006..To evaluate the patterns of recurrence when elective node irradiation was omitted in patients with limited disease small cell lung cancer (LD-SCLC)...
PET-CT in radiotherapy for lung cancerDirk De Ruysscher
Department of Radiotherapy Maastro Clinic, GROW Research Institute, Maastricht University Medical Center, Maastricht, The Netherlands
Methods Mol Biol 727:53-8. 2011..g., know patterns of tumor spread according to pathological studies, knowledge of endoscopic findings, and other tumor and patient factors) to come to target volume definitions that have proven their clinical efficacy...
PET scans in radiotherapy planning of lung cancerDirk De Ruysscher
Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center, GROW Research Institute, The Netherlands
Radiother Oncol 96:335-8. 2010..In limited-disease small cell lung cancer, the role of FDG-PET is emerging...
European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancerDirk De Ruysscher
Maastricht University Medical Center, GROW Research Institute, Department of Radiation Oncology Maastro Clinic, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
J Clin Oncol 28:5301-10. 2010..To derive recommendations for routine practice and clinical trials for techniques used in high-dose, high-precision thoracic radiotherapy for lung cancer...
Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based studyD De Ruysscher
Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Medical Center Maastricht, Maastricht, The Netherlands
Ann Oncol 20:98-102. 2009..The purpose of this prospective study was to get insight in what proportion of patients with locally advanced lung cancer would be suitable for concurrent chemoradiation...
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical studyDirk De Ruysscher
Maastro Clinic, and Department of Radiation Oncology, University Hospital Maastricht, p a Henri Dunantstraat 5, NL 6419 PC Heerlen, The Netherlands
Int J Radiat Oncol Biol Phys 62:988-94. 2005..To evaluate the patterns of recurrence when selective mediastinal node irradiation based on FDG-PET scan data is used in patients with non-small-cell lung cancer (NSCLC)...
First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-IIDirk De Ruysscher
Department of Radiotherapy Maastro Clinic, Maastricht University Medical Center, The Netherlands
Radiother Oncol 97:36-9. 2010..Identifying the most radiosensitive patient group would have huge clinical implications...
Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning studyDirk De Ruysscher
Department of Radiation Oncology MAASTRO, Maastricht, The Netherlands
Radiother Oncol 77:5-10. 2005..To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer...
Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancerD De Ruysscher
Department of Radiotherapy, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Ann Oncol 17:543-52. 2006..We undertook a systematic review and literature-based meta-analysis to determine whether the timing of chest radiotherapy may influence the survival of patients with limited-stage small-cell lung cancer (LS-SCLC)...
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancerDirk De Ruysscher
Department of Radiotherapy, University Hospital Maastricht, University Maastricht, Groel en Ontwikkeling, The Netherlands
J Clin Oncol 24:1057-63. 2006..To identify time factors for combined chemotherapy and radiotherapy predictive for long-term survival of patients with limited-disease small-cell lung cancer (LD-SCLC)...
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective studyJudith van Loon
Department of Radiation Oncology, Maastro Clinic, GROW Research Institute, Maastricht University Medical Centre, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 77:329-36. 2010..To evaluate the results of selective nodal irradiation on basis of (18)F-deoxyglucose positron emission tomography (PET) scans in patients with limited-disease small-cell lung cancer (LD-SCLC) on isolated nodal failure...
Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancerGeert Bosmans
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 71:139-44. 2008..This study describes the time trends in nodal computed tomography (CT) volume and motion for patients with locally advanced non-small-cell lung cancer (NSCLC)...
Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findingsMarco H M Janssen
Department of Radiation Oncology MAASTRO, University Medical Centre Maastricht, Maastricht, The Netherlands
Radiother Oncol 94:151-5. 2010..The purpose of this study was to prospectively investigate metabolic changes of rectal tumors after 1 week of treatment of either radiochemotherapy (28 x 1.8 Gy+Capecitabine) (RCT) or hypofractionated radiotherapy (5 x 5 Gy) alone (RT)...
Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective studyJudith van Loon
Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Medical Centre, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
Eur J Cancer 45:588-95. 2009..Because the accuracy of (18)FDG-PET-CT is superior to CT, we hypothesised that FDG-PET-CT scans 3 months post-treatment could lead to early detection of progressive disease (PD) amenable for radical treatment...
Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating studyJudith van Loon
Department of Radiation Oncology, Maastricht University Medical Centre, The Netherlands
Radiother Oncol 99:172-5. 2011..The purpose of the current study was to evaluate whether CT or FDG metabolic response early after the start of chemotherapy, but before the beginning of chest RT, is predictive for survival in SCLC...
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scanHugo J W L Aerts
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University, The Netherlands
Radiother Oncol 91:386-92. 2009..We hypothesized that areas within the tumour with a high pre-radiation (18)F-deoxyglucose (FDG) uptake, could identify residual metabolic-active areas, ultimately enabling selective-boosting of tumour sub-volumes...
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling studyAntoinet van Der Wel
Maastro Clinic, University Hospital Maastricht, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 61:649-55. 2005..The results of this modeling study support clinical trials investigating incorporation of FDG-PET information in CT-based radiotherapy planning...
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapyCary Dehing-Oberije
Department of Radiotherapy, Maastro Clinic, Research Institute of Growth and Development, University Hospital Maastricht, University Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 74:355-62. 2009..The objective of this study was to develop and validate a prediction model for survival of NSCLC patients, treated with chemoradiotherapy...
18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluationJudith van Loon
Department of Radiation Oncology Maastro Clinic, GROW Research Institute, Maastricht University Medical Centre, Maastricht, The Netherlands
Eur J Cancer 46:110-9. 2010..Here, we report on the economic evaluation of this study...
Tumor delineation based on time-activity curve differences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patientsMarco H M Janssen
Department of Radiation Oncology MAASTRO, Research Institute GROW, University Hospital Maastricht, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 73:456-65. 2009....
18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning studyJudith van Loon
Department of Radiation Oncology Maastro Clinic, GROW Research Institute, University Hospital Maastricht, Maastricht, The Netherlands
Radiother Oncol 87:49-54. 2008..To investigate the influence of selective irradiation of 18FDG-PET positive mediastinal nodes on radiation fields and normal tissue exposure in limited disease small cell lung cancer (LD-SCLC)...
[¹⁸F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patientsSteven F Petit
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 81:698-705. 2011..The relationship between pretreatment [(18)F]fluorodeoxyglucose ([(18)F]FDG) uptake in the lungs (as a surrogate for inflammation) and the delivered radiation dose and radiation-induced lung toxicity (RILT) was investigated...
Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility studyAngela van Baardwijk
Department of Radiation Oncology MAASTRO, GROW Research Institute, University Hospital Maastricht, Dr Tanslaan 12, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 71:1394-401. 2008..We report first results of a prospective feasibility trial...
Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancerErik Roelofs
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
J Thorac Oncol 7:165-76. 2012..The hypothesis is that proton radiotherapy decreases the dose and the volume of irradiated normal tissues even when escalating to the maximum tolerable dose of one or more of the organs at risk (OAR)...
Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical studySteven F Petit
Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
Radiother Oncol 91:393-8. 2009..To characterize the relationship between pre-radiotherapy (18)Fluorodeoxyglucose (FDG) uptake in a tumour voxel, radiation dose and the probability to achieve metabolic control in the tumour voxel after radiotherapy...
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patientsAngela van Baardwijk
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Radiother Oncol 82:145-52. 2007..We investigated changes in FDG uptake during fractionated radiotherapy in relation to metabolic response with the ultimate aim to adapt treatment according to early response...
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapyCary Dehing-Oberije
Department of Radiotherapy, University Hospital Maastricht, University Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 70:1039-44. 2008..In this study, we investigated the prognostic value of tumor volume and N status, assessed by using fluorodeoxyglucose-positron emission tomography (PET)...
Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility studyAngela van Baardwijk
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Radiother Oncol 87:55-8. 2008..For this purpose we used an ex-vivo model. The procedure was feasible in all operated patients. We have shown that this method is suitable for correlating intra-tumour heterogeneity in tracer uptake with histology...
Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical studyGeert Bosmans
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 66:748-53. 2006..The aim of this study was to investigate the change in tumor volume, motion, and breathing frequency during a course of radiotherapy, for locally advanced non-small-cell lung cancer...
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450)Dirk De Ruysscher
Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, University Medical Centre Maastricht, Maastricht, The Netherlands
J Thorac Oncol 7:1547-55. 2012....
Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based studyRinus Wanders
Department of Radiation Oncology, Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
Eur J Cancer 47:2691-7. 2011..There is little data on the survival of elderly patients with stage III non-small cell lung cancer (NSCLC)...
Should patient setup in lung cancer be based on the primary tumor? An analysis of tumor coverage and normal tissue dose using repeated positron emission tomography/computed tomography imagingWouter van Elmpt
Department of Radiation Oncology, MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 82:379-85. 2012..Evaluation of the dose distribution for lung cancer patients using a patient setup procedure based on the bony anatomy or the primary tumor...
The use of FDG-PET to target tumors by radiotherapyGuido Lammering
Maastro Clinic, Radiation Oncology, Maastricht, The Netherlands
Strahlenther Onkol 186:471-81. 2010..Besides for staging purposes, FDG-PET is not recommended for routine radiotherapy delineation purposes. It should be emphasized that using PET is only safe when adhering to strictly standardized protocols...
Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patientsCary Dehing-Oberije
Department of Radiotherapy, Maastricht University Medical Center, University Maastricht, Maastro Clinic, GROW, The Netherlands
Radiother Oncol 97:455-61. 2010..Therefore, we have developed and validated a nomogram to predict this side-effect. In addition, clinical usefulness was assessed by comparing model predictions to physicians' predictions...
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumesAngela van Baardwijk
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 68:771-8. 2007....
Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trialAngela van Baardwijk
Department of Radiation Oncology MAASTRO, GROW Research Institute University Hospital Maastricht, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 71:1103-10. 2008..We investigated the theoretical gain in the estimated tumor control probability (TCP) using an individualized maximal tolerable dose (MTD) prescription, for both conventional and accelerated fractionation schemes...
Health-related quality of life in patients surviving non-small cell lung cancerJanneke P C Grutters
Department of Health Organization, Policy and Economics, Caphri Research Institute, Maastricht University, Maastricht, The Netherlands
Thorax 65:903-7. 2010..In this study, the EQ-5D was used to assess HRQoL in survivors of non-small cell lung cancer (NSCLC). The influence of tumour stage, adverse events, initial treatment and presence of recurrence was examined...
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validationHugo J W L Aerts
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
Lung Cancer 75:73-6. 2012..Therefore, a pre-radiotherapy FDG-PET-CT scan can potentially be used for radiotherapy dose redistribution...
The importance of patient characteristics for the prediction of radiation-induced lung toxicityCary Dehing-Oberije
Department of Radiotherapy, University Maastricht, GROW, Maastricht, The Netherlands
Radiother Oncol 91:421-6. 2009..We investigated the predictive value of patient characteristics in combination with established dosimetric parameters...
Volume or position changes of primary lung tumor during (chemo-)radiotherapy cannot be used as a surrogate for mediastinal lymph node changes: the case for optimal mediastinal lymph node imaging during radiotherapyWouter van Elmpt
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 79:89-95. 2011..The purpose of this study was to investigate the relationship between the positional and volumetric changes in primary tumors and the involved LN during (chemo)radiotherapy treatment of non-small-cell lung cancer patients...
Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancerAngela van Baardwijk
Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Eur J Cancer 48:2339-46. 2012..We therefore performed a phase II trial (clinicaltrials.gov; NCT00572325) investigating the same strategy in concurrent chemo-radiation in stage III NSCLC...
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planningAngela van Baardwijk
University of Maastricht, GROW Research Institute, Maastricht, The Netherlands
Cancer Treat Rev 32:245-60. 2006..In most other tumour sites not enough data are currently available to draw definitive conclusions about the role of PET in radiation treatment planning...
Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT0Cary Dehing-Oberije
Department of Radiation Oncology Maastro Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 81:360-8. 2011..The hypothesis of this prospective study was that blood biomarkers related to hypoxia, inflammation, and tumor load would have an added prognostic value for predicting survival...
Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?Roy F A Vliegen
Department of Radiology, University Hospital Maastricht, Maastricht, The Netherlands
Strahlenther Onkol 184:457-64. 2008..So far, MRI and CT have failed to provide such information. Therefore, the value of a combined FDG-PET/CT in predicting tumor clearance of the mesorectal fascia (MRF) was determined...
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancerAngela van Baardwijk
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands
Eur J Cancer 43:1392-8. 2007..9% versus 62.5%, p=0.025), than tumours with a low SUV(max). No significant difference was found in the expression of CAIX, Ki-67 and GLUT-3. This study supports preclinical data that hypoxia is associated with a higher uptake of FDG...
PET imaging of hypoxia using [18F]HX4: a phase I trialJudith van Loon
Department of Radiation Oncology Maastro Clinic, GROW School of Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Eur J Nucl Med Mol Imaging 37:1663-8. 2010..In this phase I trial, we aimed to determine the toxicity of [(18)F]HX4, a member of the 2-nitroimidazole family, at different dose levels. The secondary aim was to analyse image quality related to the HX4 dose and the timing of imaging...
The integration of PET-CT scans from different hospitals into radiotherapy treatment planningMichel Ollers
Department of Radiation Oncology MAASTRO, University Hospital Maastricht, Maastricht, The Netherlands
Radiother Oncol 87:142-6. 2008..To integrate PET-CT scans from different hospitals into radiotherapy treatment planning...
Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancerJudith van Loon
Maastricht University Medical Centre, Department of Radiation Oncology, Maastro Clinic, GROW Research Institute, The Netherlands
Cancer Treat Rev 37:331-43. 2011..Tracers other than (18)FDG are promising for treatment response assessment and the visualization of intra-tumor heterogeneity, but more research is needed before they can be clinically implemented...
FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot studyJos J Jager
Maastro Clinic, Department of Radiation Oncology, 6202 NA Maastricht, The Netherlands
Acta Oncol 49:185-91. 2010..To determine the additional value of FDG-PET-CT as compared to conventional staging (CS) in high-risk breast cancer patients...
An "in silico" clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patientsGeert Bosmans
Department of Radiation Oncology MAASTRO, GROW, University Hospital Maastricht, Maastricht, The Netherlands
Radiother Oncol 81:73-80. 2006..To determine which method of internal target volume (ITV) definition based on a respiration correlated CT (RCCT) allows optimal tumor coverage...
High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoLMadelon Pijls-Johannesma
Department of Radiation Oncology Maastro Clinic, Maastricht, The Netherlands
Radiother Oncol 91:443-8. 2009..The purpose of this study was to investigate the evolution of quality of life (QoL) in patients with lung cancer, selected for curative radiotherapy (RT) or chemo-RT...
Palliative chest irradiation in sitting position in patients with bulky advanced lung cancerCindy Duisters
Department of Radiation Oncology (MAASTRO, GROW, University Hospital Maastricht, The Netherlands
Radiother Oncol 79:285-7. 2006..The reproducibility of the sitting position was high and all ten patients preferred this position over lying down. In selected patients who are unable to lie down, palliative irradiation in a sitting position may be an option...
Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective studyHugo J W L Aerts
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, University Hospital Maastricht, Dr Tanslaan 12, Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 71:1402-7. 2008..To do this, it is critical to know whether the location of these high FDG uptake patterns within the tumor remain stable during radiotherapy (RT)...
Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature reviewMadelon Pijls-Johannesma
Maastricht Radiation Oncology MAASTRO Clinic, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands
Oncologist 15:93-103. 2010..In this review, we searched for clinical evidence to justify implementation of particle therapy as standard treatment in lung cancer...
Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumoursWouter van Elmpt
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Dr Tanslaan 12, NL 6229 ET Maastricht, The Netherlands
Eur J Nucl Med Mol Imaging 38:843-55. 2011..We investigated the added value of a new respiratory amplitude-based PET reconstruction method called optimal gating (OG) with the aim of providing accurate image quantification in lung cancer...
Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysisJanneke P C Grutters
Department of Radiation Oncology Maastro Clinic, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands
Radiother Oncol 95:32-40. 2010..To provide a comparison between radiotherapy with photons, protons and carbon-ions in the treatment of Non-Small-Cell Lung Cancer (NSCLC), performing a meta-analysis of observational studies...
3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancerWouter van Elmpt
Department of Radiation Oncology MAASTRO, Maastricht University Medical Centre, The Netherlands
Radiother Oncol 94:188-94. 2010..To implement a 3D dose verification procedure, based on in-room cone-beam CT imaging and portal dosimetry, for lung cancer patients treated with stereotactic body radiotherapy (SBRT)...
A systematic methodology review of phase I radiation dose escalation trialsMadelon Pijls-Johannesma
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
Radiother Oncol 95:135-41. 2010..The purpose of this review is to evaluate the methodology used in published phase I radiotherapy (RT) dose escalation trials. A specific emphasis was placed on the frequency of reporting late complications as endpoint...
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancerPhilippe Lambin
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
Radiother Oncol 96:145-52. 2010..The administration of these complicated dose distributions requires a quality assurance procedure that can evaluate the treatment delivery and, if necessary, adapt the treatment plan during radiotherapy...
Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patientsLudy C H W Lutgens
Department of Radiation Oncology MAASTRO, University Hospital Maastricht, Maastricht University, Dr Tanslan 12, 6229 ET Maastricht, The Netherlands
Int J Radiat Oncol Biol Phys 60:275-85. 2004..Our objective was to evaluate the feasibility of citrulline as a marker for radiation-induced small-intestinal mucosal atrophy in patients during and after abdominal fractionated radiotherapy...
Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trialsMadelon Pijls-Johannesma
Maastro Clinic, University Hospital, Dr Tanslaan 12, 6229 ET Maastricht, The Netherlands
Cancer Treat Rev 33:461-73. 2007..We undertook a systematic review and literature-based meta-analysis to determine whether the timing of chest radiotherapy may influence the survival of patients with limited stage small cell lung cancer (LS-SCLC)...
Prediction of residual metabolic activity after treatment in NSCLC patientsEmmanuel Rios Velazquez
Department of Radiation Oncology MAASTRO, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center MUMC, Maastricht, The Netherlands
Acta Oncol 49:1033-9. 2010..We report on the development of a pre-treatment prediction model for metabolic response using patient, tumor and treatment factors...
Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancerAngela van Baardwijk
Department of RadiationOncology MAASTRO, GROWResearch Institute, Maastricht UniversityMedical Center, Maastricht
J Clin Oncol 28:1380-6. 2010..Here, we report the mature results of a prospective, single-arm study that used this individualized tolerable dose approach...
Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian surveyDirk De Ruysscher
University Hospital Maastricht, Department of Radiation Oncology, Dr Tanslaan 12, NL-6229 ET Maastricht, The Netherlands
Radiother Oncol 68:299-302. 2003....
Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patientsJonathan Orban de Xivry
Communications and Remote Sensing Laboratory TELE, Universite Catholique de Louvain, Louvain la Neuve, Belgium
Radiother Oncol 85:232-8. 2007..To improve treatment planning in radiotherapy for non-small cell lung cancer by including Respiratory Correlated-Computed Tomography (RC-CT) information in tumour delineation and dose planning...
Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvementCécile Le Péchoux
J Clin Oncol 25:e10-1. 2007
Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility studyDirk De Ruysscher
Department of Radiation and Medical Oncology, Sint-Maarten Ziekenhuis, Rooienberg 25, 2570 Duffel, Belgium
Radiother Oncol 64:33-6. 2002..All toxicities were reversible, with only two of ten patients experiencing grade 3 oesophagitis, no treatment-related deaths and no serious late effects...
A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancerMark Lodge
Cochrane Cancer Network, Oxford, UK
Radiother Oncol 83:110-22. 2007..In view of the continued increase in the number of hadron (i.e. neutron, proton and light or heavy ion) therapy (HT) centres we performed a systematic literature review to identify reports of the efficacy of HT...
Proton therapy in clinical practice: current clinical evidenceMichael Brada
The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
J Clin Oncol 25:965-70. 2007
